Highest-materiality recent filing
DSS enters $2.45M convertible note and warrant deal with related party Alset International
Loan of $2,450,000 via convertible promissory note at 3% simple interest.
DSS converts $12M Impact Biomedical debt into 31.9M shares of Impact common stock
DSS settled all outstanding debt owed by Impact Biomedical under a $12M original note and amendments.
DSS restates 2023 10-K; $23.5M overstatement of deconsolidation loss, discontinued ops omitted
Audit Committee determined 2023 10-K financials unreliable due to errors; restated via 10-K/A filed Oct 22, 2024.
CEO Frank Heuszel to step down; Jason Grady appointed interim CEO
Frank Heuszel resigns as CEO effective Aug 23, 2024; no disagreement with company on operations, policies, or practices.
Mr. Frank D. Heuszel, announced that effective on the close of business on August 23, 2024, he will step down as the Chief Executive Officer
Effective August 23, 2024, the Board of Directors of DSS, Inc. elected Mr. Jason Grady as the Company’s new Interim Chief Executive Officer.
Effective August 23, 2024, the Board of Directors of DSS, Inc. elected Mr. Jason Grady as the Company’s new Interim Chief Executive Officer.
Mr. Frank D. Heuszel, announced that effective on the close of business on August 23, 2024, he will step down as the Chief Executive Officer of DSS.
Max materiality 0.85 · Median 0.50 · Most common event other_material